Olaitan Adeniji, MD
Gastroenterology · Snellville, GANPI 1255321089
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Redhill Biopharma Inc. at 33.2% of the total. Reporting peaked in 2020 at $6,710 and has fallen 73.1% since, to $1,805 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $48.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$7K
- AbbVie$5K
- Intercept Pharmaceuticals, Inc.$4K
- Johnson & Johnson$671
- Gilead$658
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$530
- plus $4K from 29 others
Across 1 payment — averaging $400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$400
What the payments were for
- Consulting fees$1,6658%
- Speaking & faculty fees$9,70544%
- Travel & lodging$7273%
- Food & beverage$9,95245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 37 | $7,317 |
| AbbVie(2 entities) | 137 | $5,019 |
| Intercept Pharmaceuticals, Inc. | 15 | $3,991 |
| Johnson & Johnson | 23 | $671 |
| Gilead | 32 | $658 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $530 |
| Sanofi | 19 | $457 |
| Regeneron Healthcare Solutions, Inc. | 11 | $377 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $324 |
| Pfizer | 17 | $274 |
| Bristol Myers Squibb | 16 | $243 |
| E.r. Squibb & Sons, L.L.C. | 2 | $219 |
| Ipsen Biopharmaceuticals, Inc | 5 | $211 |
| Ironwood Pharmaceuticals, Inc | 13 | $190 |
| Boston Scientific | 3 | $170 |
| Ardelyx, Inc. | 2 | $145 |
| Phathom Pharmaceuticals, Inc. | 12 | $121 |
| Ferring Pharmaceuticals Inc. | 7 | $121 |
| Madrigal Pharmaceuticals | 6 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $111 |
| Braintree Laboratories, Inc. | 6 | $109 |
| Merck | 7 | $104 |
| Amgen | 5 | $103 |
| Nestle Healthcare Nutrition Inc. | 5 | $90 |
| Daiichi Sankyo Inc. | 5 | $79 |
| Celltrion USA Inc. | 2 | $53 |
| Fresenius Kabi USA, LLC | 3 | $51 |
| UCB, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Shionogi Inc | 2 | $28 |
| Medtronic | 1 | $17 |
| Intra-sana Laboratories | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,049 in reported general payments places this provider in the 90th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 61 | $70,061 |
| VemlidyTenofovir Alafenamide | 13 | $21,274 |
| Mesalamine | 16 | $9,087 |
| MovantikNaloxegol Oxalate | 13 | $5,968 |
| Omeprazole | 286 | $4,857 |
| Mesalamine ErMesalamine | 11 | $3,048 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 180 | $2,609 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 15 | $2,399 |
| Pantoprazole Sodium | 121 | $2,010 |
| Ondansetron OdtOndansetron | 26 | $1,819 |
| Sucralfate | 31 | $771 |
| Lactulose | 36 | $632 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 30 | $469 |
| Famotidine | 12 | $258 |
| Metronidazole | 20 | $251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $5,019 | $70,06161 claims |
| GileadVemlidy | $658 | $21,27413 claims |
| Redhill Biopharma Inc.Movantik | $7,317 | $5,96813 claims |
| Braintree Laboratories, Inc.Sutab | $109 | $2,39915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Snellville
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Satish RaoAugusta$335K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Aja McCutchenWinder$310K
- Bruce SalzbergSuwanee$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.